SELECT FROM MENU

Therapy Areas
Drug Classes

       Therapy Areas

All Sessions

All Sessions

Resectable NSCLC

Resectable NSCLC

Advanced NSCLC

Advanced NSCLC

SCLC

SCLC

Biomarkers

Biomarkers

       Drug Classes

Targeted Therapies

Targeted Therapies

Immunotherapies

Immunotherapies

ADCs

ADCs

Martin Reck

Martin Reck

LungenClinic Grosshansdorf

Prof. Martin Reck heads the Department of Thoracic Oncology at LungenClinic Grosshansdorf in Germany. He has led pivotal first-line immunotherapy trials in metastatic NSCLC, including KEYNOTE-024, and continues to drive evidence generation across the lung cancer treatment landscape. He is a frequent speaker at major international congresses.

Connect

Martin Reck

Featured in

Prof. Martin Reck
Nov 04 2026
SPONSORED EXPERT TALK
Resectable NSCLCImmunotherapies

MDT-BRIDGE in Resectable and Borderline Resectable NSCLC

Prof. Martin Reck presents and discusses the phase 2 MDT-BRIDGE trial in resectable and borderline resectable non-small cell lung cancer in this on-demand expert talk.

M. Reck
Jacob Sands, Solange Peters and Martin Reck
Dec102026
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2026 Year in Review

Learn more about the event

S. PetersJ. SandsM. Reck
Martin Reck
Oct 30 2026
RESEARCH
Advanced NSCLCResectable NSCLCImmunotherapies

Neoadjuvant durvalumab plus chemotherapy led to resection in 74.6% of patients in the MDT-BRIDGE trial

Read the article

M. ReckN. GirardA. Filippi
Oct252026
ESMO 2026 SYMPOSIUM
SCLCImmunotherapies

SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era

A symposium at ESMO Congress 2026 on small-cell lung cancer, from immunotherapy standards to the emerging era of DLL3 T-cell engagers. Recording to follow.

M. ReckS. PetersG. MountziosN. Reguart
Oct 23 2026
RESEARCH
SCLCImmunotherapies

KEYVIBE-008 tested vibostolimab coformulated with pembrolizumab plus chemotherapy in first-line ES-SCLC

Read the article

J. SandsM. Reck
Nikolaj Frost
Oct 04 2026
RESEARCH
Advanced NSCLCSCLCTargeted Therapies

Checkpoint inhibitors were associated with longer survival in NSCLC after allogeneic stem cell transplantation

Read the article

N. FrostM. ReckA. Cortellini
Oct 04 2026
RESEARCH
SCLCImmunotherapies

Longer OS in Asian than non-Asian patients given atezolizumab plus chemotherapy for extensive-stage SCLC

Read the article

S. LiuM. ReckC. Rudin
Martin Reck
Sep 28 2026
RESEARCH
Resectable NSCLCImmunotherapies

AEGEAN’s second interim analysis kept the EFS benefit of perioperative durvalumab, on an OS reading that crosses 1

Read the article

M. ReckM. Hochmair
Aug 02 2026
RESEARCH
Resectable NSCLCImmunotherapies

Five-year event-free survival was 49.9% with perioperative pembrolizumab against 26.5% in KEYNOTE-671

Read the article

D. Rodríguez-AbreuM. Reck
Jul 14 2026
RESEARCH
Advanced NSCLCADCs

Trastuzumab deruxtecan in HER2-mutant NSCLC: evidence from the largest real-world cohort to date

Read the article

M. HochmairG. MountziosA. AddeoM. Reck
Lung Cancer Review by Solange Peters, Martin Reck, Charles Rudin
Dec 18 2025
VIRTUAL ROUNDTABLE
Advanced NSCLCSCLCADCs

2025 Approvals & Highlights

} 1 h 49 min

S. PetersC. RudinM. Reck